Joe Keegan, CEO of Molecular Devices, greeted analysts at last week’s quarterly conference call by calling the period “the best third quarter in the company’s history.”

Keegan, who has been president and CEO of the 21-year-old company since 1998, was mixed in his outlook, however, noting that the company was surprised by weakness in the drug-discovery market and a slowdown in capital spending for high-dollar tools.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.